Calls Popular As Incyte Stock Cheers Cancer Drug Data

Calls Popular As Incyte Stock Cheers Cancer Drug Data

Earlier today, Incyte Corporation (NASDAQ:INCY) reported upbeat results from its mid-stage study of Capmatinib, the company’s lung cancer treatment sponsored by Novartis (NOVN). Incyte Corporation says the successful development could net over $500 million in future milestones. INCY stock is up 3.4% to trade at $66.56 as a result, and options traders are piling on in […]

TP Therapeutics raises $80 million for cancer drugs

TP Therapeutics raises $80 million for cancer drugs

Local drugmaker TP Therapeutics has brought in $80 million to push forward its research for a cancer therapy to treat tumors that are resistant to existing cancer drugs. The company, which made the announcement Friday, plans to put the cash to work funding a mid-stage trial that tests its drug, reptrectinib, in humans. The therapy […]

Orphan Drug for Pancreatic Cancer Tops SPT Week in Review

Orphan Drug for Pancreatic Cancer Tops SPT Week in Review

5. How Blockchain Technology Will Impact Specialty Pharmacy The benefits of adopting blockchain technology have not been overlooked by the health care industry and can have a direct and lasting impact on specialty pharmacy. Read more.   4. FDA OKs Treatment for HER2-Negative Breast Cancer with Germline BRCA Mutation   Talazoparib is indicated for […]

Protein mTOR regulated by Src in cancer growth

Protein mTOR regulated by Src in cancer growth

Researchers at Baylor College of Medicine and Texas Children’s Hospital have identified a connection between cancer proteins mTORC1 and Src… Researchers at Baylor College of Medicine and Texas Children’s Hospital have revealed a connection between mTORC1 and Src, two proteins known to be hyperactive in cancer. The study shows that Src is necessary and sufficient to […]

Merrimack Pharma's stock plunges (again) on its latest cancer drug trial flop

Merrimack Pharma's stock plunges (again) on its latest cancer drug trial flop

Richard Peters Merrimack Pharmaceuticals $MACK has another loser on its hands. The drug MM-121 (seribantumab) added to docetaxel did not do any better than docetaxel alone in improving the progression-free survival of patients suffering from non-small cell lung cancer. Merrimack’s stock, already blighted by trial failure, quickly plunged anew, dropping more than 30% on the […]

TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push

TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push

Xconomy San Diego —  Five-year-old biotech TP Therapeutics has raised an $80 million mezzanine financing round and promoted its chief medical officer, Athena Countouriotis, to CEO. The San Diego-based biotech, which is developing targeted cancer drugs for people whose tumors resist other precision therapies, announced the changes Friday. TP Therapeutics is developing a drug called […]